Headline News

 

PADCEV plus Keytruda secures US FDA approval as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer irrespective of cisplatin eligibility

Posted on July 13, 2026

Sanofi’s subcutaneous Sarclisa Escena becomes the first anticancer therapy delivered via an on-body injector to win US approval

Posted on July 13, 2026

FDA approves expanded use of Vertex’s CASGEVY for people aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia

Posted on July 07, 2026

Vertex set to acquire Crinetics Pharmaceuticals, adding endocrinology assets with significant commercial and pipeline potential

Posted on July 07, 2026

Novartis secures European Commission approval for Itvisma in spinal muscular atrophy

Posted on July 07, 2026

Novartis set to acquire Myricx Bio for next-generation antibody-drug conjugate innovation and a novel NMTi payload platform into its oncology arsenal

Posted on July 07, 2026

BeOne Medicines highlights positive Phase 3 findings for BRUKINSA in frontline mantle cell lymphoma

Posted on July 07, 2026

FDA grants Priority Review to Roche’s Enspryng, a potential first at-home subcutaneous treatment for thyroid eye disease

Posted on July 07, 2026

Roche’s divarasib demonstrates superiority in head-to-head Phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

Posted on July 07, 2026

Roche to share new Alzheimer’s disease findings from its integrated pharmaceutical and diagnostics portfolio at AAIC

Posted on July 07, 2026

European Commission grants marketing authorisation for AbbVie’s TEPKINLY combined with lenalidomide and rituximab in relapsed or refractory follicular lymphoma

Posted on July 07, 2026

Nexviazyme achieves all primary and secondary endpoints in Sanofi’s infantile-onset Pompe disease Phase 3 trial

Posted on July 07, 2026

Roche unveils AXELIOS 1, which is a next-generation sequencing platform set to transform genomic research

Posted on June 29, 2026

GSK announces launch of tender offer to acquire Nuvalent

Posted on June 29, 2026

Efzimfotase alfa highlights meaningful bone health improvements in treatment-naïve paediatric patients with hypophosphatasia, achieving a median difference of 1.67 versus placebo in RGI-C score at week 25 in the MULBERRY Phase III trial

Posted on June 29, 2026